(Cost-)effectiveness of self-treatment of exacerbations in patients with COPD: 2 years follow-up of a RCT

Respirology

Volumn 21, Issue 3, 2016, Pages 497-503

  Zwerink, Marlies ^a   Kerstjens, Huib A M ^b   Van Der Palen, Job ^a,c   Van Der Valk, Paul ^a   Brusse Keizer, Marjolein ^a   Zielhuis, Gerhard ^d   Effing, Tanja ^e,f  

^a MEDISCH SPECTRUM TWENTE   (Netherlands)

^b UNIVERSITY OF TWENTE   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e REPATRIATION GENERAL HOSPITAL   (Australia)

^f FLINDERS UNIVERSITY   (Australia)

Author keywords

Chronic obstructive pulmonary disease; Cost effectiveness; Exacerbation; Quality of life; Self management

Indexed keywords

ANTIBIOTIC AGENT; PREDNISOLONE; GLUCOCORTICOID;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; INCIDENCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SELF CARE; TREATMENT PLANNING; AGED; CONTRAINDICATIONS; COST BENEFIT ANALYSIS; DOSE RESPONSE; ECONOMICS; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE;

ADULT; AGED; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; PREDNISOLONE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; SELF CARE;

EID: 84949883212     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12697     Document Type: Article

References (32)

1. Gibson GJ, Loddenkemper R, Sibille Y, Lundbäck B,. The European Lung White Book. European Respiratory Society, Sheffield, 2013.
2. Toy EL, Gallagher KF, Stanley EL, Swensen AR, Duh MS,. The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review. COPD 2010; 7: 214-228.
3. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 2007; 176: 532-555.
4. Suissa S, Dell'Aniello S, Ernst P,. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax 2012; 67: 957-963.
5. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA,. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 157 (5 Pt 1): 1418-1422.
6. Jones P, Lareau S, Mahler DA,. Measuring the effects of COPD on the patient. Respir. Med. 2005; 99 (Suppl. B): S11-18.
7. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA,. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847-852.
8. Xu W, Collet JP, Shapiro S, Lin Y, Yang T, Wang C, Bourbeau J,. Negative impacts of unreported COPD exacerbations on health-related quality of life at 1 year. Eur. Respir. J. 2010; 35: 1022-1030.
9. Wilkinson TM, Donaldson GC, Hurst JR, Seemungal TA, Wedzicha JA,. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2004; 169: 1298-1303.
10. Langsetmo L, Platt RW, Ernst P, Bourbeau J,. Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort. Am. J. Respir. Crit. Care Med. 2008; 177: 396-401.
11. Trappenburg JC, Monninkhof EM, Bourbeau J, Troosters T, Schrijvers AJ, Verheij TJ, Lammers JW,. Effect of an action plan with ongoing support by a case manager on exacerbation-related outcome in patients with COPD: a multicentre randomised controlled trial. Thorax 2011; 66: 977-984.
12. Stone R, Lowe D, Buckingham R, Pursey N, Potter J, Roberts CM,. What happens to COPD patients before an admission with exacerbation? Prim. Health Care Res. Dev. 2012; 13: 395-402.
13. Walters JA, Turnock AC, Walters EH, Wood-Baker R,. Action plans with limited patient education only for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2010; (5): CD005074.
14. Zwerink M, Brusse-Keizer M, van der Valk PD, Zielhuis GA, Monninkhof EM, van der Palen J, Frith PA, Effing T,. Self management for patients with chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2014; (3): CD002990.
15. Effing T, Kerstjens H, van der Valk P, Zielhuis G, van der Palen J,. Cost)-effectiveness of self-treatment of exacerbations on the severity of exacerbations in patients with COPD: the COPE II study. Thorax 2009; 64: 956-962.
16. Effing T, Zielhuis G, Kerstjens H, van der Valk P, van der Palen J,. Community based physiotherapeutic exercise in COPD self-management: a randomised controlled trial. Respir. Med. 2011; 105: 418-426.
17. Altman DG, Bland JM,. Treatment allocation by minimisation. BMJ 2005; 330: 843.
18. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA,. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 1987; 106: 196-204.
19. Puhan MA, Behnke M, Laschke M, Lichtenschopf A, Brandli O, Guyatt GH, Schunemann HJ,. Self-administration and standardisation of the chronic respiratory questionnaire: a randomised trial in three German-speaking countries. Respir. Med. 2004; 98: 342-350.
20. van der Molen T, Willemse BW, Schokker S, ten Hacken NH, Postma DS, Juniper EF,. Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual. Life Outcomes 2003; 1: 13.
21. Zigmond AS, Snaith RP,. The hospital anxiety and depression scale. Acta Psychiatr. Scand. 1983; 67: 361-370.
22. Hakkaart-van Roijen L, Tan SS, Bouwmans CAM, Handleiding voor kostenonderzoek. College voor Zorgverzekeringen; 2010.
23. Bischoff EW, Akkermans R, Bourbeau J, van Weel C, Vercoulen JH, Schermer TR,. Comprehensive self management and routine monitoring in chronic obstructive pulmonary disease patients in general practice: randomised controlled trial. BMJ 2012; 345: e7642.
24. Bucknall CE, Miller G, Lloyd SM, Cleland J, McCluskey S, Cotton M, Stevenson RD, Cotton P, McConnachie A,. Glasgow supported self-management trial (GSuST) for patients with moderate to severe COPD: randomised controlled trial. BMJ 2012; 344: e1060.
25. Khdour MR, Agus AM, Kidney JC, Smyth BM, McElnay JC, Crealey GE,. Cost-utility analysis of a pharmacy-led self-management programme for patients with COPD. Int. J. Clin. Pharm. 2011; 33: 665-673.
26. Dewan NA, Rice KL, Caldwell M, Hilleman DE,. Economic evaluation of a disease management program for chronic obstructive pulmonary disease. COPD 2011; 8: 153-159.
27. Hoogendoorn M, van Wetering CR, Schols AM, Rutten-van Molken MP,. Is INTERdisciplinary COMmunity-based COPD management (INTERCOM) cost-effective? Eur. Respir. J. 2010; 35: 79-87.
28. Bourbeau J, Collet JP, Schwartzman K, Ducruet T, Nault D, Bradley C,. Economic benefits of self-management education in COPD. Chest 2006; 130: 1704-1711.
29. Effing TW, Bourbeau J, Vercoulen J, Apter AJ, Coultas D, Meek P, Valk P, Partridge MR, Palen J,. Self-management programmes for COPD: moving forward. Chron. Respir. Dis. 2012; 9: 27-35.
30. Fan VS, Gaziano JM, Lew R, Bourbeau J, Adams SG, Leatherman S, Thwin SS, Huang GD, Robbins R, Sriram PS, et al. A comprehensive care management program to prevent chronic obstructive pulmonary disease hospitalizations: a randomized, controlled trial. Ann. Intern. Med. 2012; 156: 673-683.
31. Schnell K, Weiss CO, Lee T, Krishnan JA, Leff B, Wolff JL, Boyd C,. The prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-sectional study using data from NHANES. BMC Pulm. Med. 1999-2008; 2012: 12-26.
32. Lenferink A, Frith P, van der Valk P, Buckman J, Sladek R, Cafarella P, van der Palen J, Effing T,. A self-management approach using self-initiated action plans for symptoms with ongoing nurse support in patients with chronic obstructive pulmonary disease (COPD) and comorbidities: the COPE-III study protocol. Contemp. Clin. Trials 2013; 36: 81-89.